Imatinib
Chronic Myelomonocytic Leukemia
OHSU Knight Cancer InstituteSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 73/ 100
Competitive context
98 Active assets in the Chronic Myelomonocytic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pevonedistat Takeda | Phase 3 | BB |
Venetoclax Servier Bio-Innovation LLC | Phase 2/3 | BB |
Astx727 Taiho Oncology, Inc. | Phase 3 | BB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | BB |
Evomela City of Hope Medical Center | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →